Skip to content
Ligand Pharmaceuticals logo

Ligand Pharmaceuticals

LGND

Ligand Pharmaceuticals is a biopharmaceutical royalty company that specializes in acquiring and managing diversified royalty streams from high-value medicines.

Market cap
$5.96B+129%
Revenue$274.5M+51.2%
Net income$153.6M+216%
Free cash flow$123.0M+142%
EPS (diluted)$7.43+204%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$61.4M
EPS estimate$1.84

Financials

Q1 2026

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation & ratios

Valuation

See full
Market cap$5.96B+129%
Enterprise value$5.85B+130%
P/E38.8×
P/S21.7×+7.8×

Profitability

See full
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Segments

By product

See full
Filspari$11.3M+114%
Captisol$8.7M
Kyprolis$6.7M
Qarziba$6.3M+15.7%
Ohtuvayre inventors$3.0M

By segment

See full
Development and Licensing of Biopharmaceutical Assets$51.7M+14.1%

Competitors

Profile

Ligand Pharmaceuticals is a biopharmaceutical royalty company that specializes in acquiring and managing diversified royalty streams from high-value medicines. The company deploys capital through royalty purchases, development-stage financing, and strategic acquisitions of assets with embedded royalty rights. Its business model focuses on generating long-duration, non-dilutive cash flows with a lean corporate infrastructure by leveraging the R&D and commercial capabilities of its partners.

Competitive position

Ligand occupies a niche as a high-margin royalty aggregator with significant operating expertise, differentiating itself from traditional biotech firms by avoiding high-cost R&D infrastructure.

GeographiesUnited States, Europe, China, Japan
Customer segmentsGlobal Pharmaceutical Companies, Mid-stage Biotech Firms, Medical Research Institutions
Business modelRoyalty Aggregator, IP Licensing, Specialty Finance
SuppliersContract manufacturing organizations, Raw material suppliers for Captisol, Academic research and early-stage biotech innovation
CustomersGlobal pharmaceutical commercialization partners, Healthcare providers, Patients requiring specialty medicines
Listed1994
Employees58.0
CEOTodd C. Davis
Websiteligand.com
FilingsSEC EDGAR

Questions, answered.

What is Ligand Pharmaceuticals's market cap?
Ligand Pharmaceuticals (LGND) has a market capitalization of $6.0B and trades on NASDAQ.
What is Ligand Pharmaceuticals's revenue and profitability?
Ligand Pharmaceuticals generated $274.5M in trailing twelve-month revenue with net income of $153.6M, representing a net margin of 55.9%. Gross margin stands at 91.9%, with free cash flow of $123.0M. These figures are based on the Q1 2026 filing.
Who are Ligand Pharmaceuticals's competitors?
Ligand Pharmaceuticals's key competitors include Royalty Pharma, Roivant Sciences Ltd. Common Shares, Rigel Pharmaceuticals Inc. (New), and others. These companies compete in similar markets and product categories.
Who does Ligand Pharmaceuticals partner with?
Ligand Pharmaceuticals's notable partners include Amgen, Merck, Travere Therapeutics, and others.
What subsidiaries does Ligand Pharmaceuticals have?
Ligand Pharmaceuticals's subsidiaries include CyDex Pharmaceuticals, Ligand UK Development Limited, Pelthos Therapeutics, and others.
Where is Ligand Pharmaceuticals headquartered?
Ligand Pharmaceuticals is headquartered in United States of America and employs approximately 58 people. It has been publicly traded since 1994.